HIV pre-exposure prophylaxis study finds TAF has higher risk of hypertension than TDF

Researchers at Kaiser Permanente Southern California, Pasadena, have found that in patients taking pre-exposure prophylaxis (PrEP), tenofovir alafenamide fumarate (TAF) use associated with higher incidents of hypertension and statin initiation compared with the alternative formulation tenofovir disoproxil fumarate (TDF), especially in those 40 years or older.